Tocagen Inc. and Forte Biosciences, Inc., a privately held clinical-stage biopharmaceutical company developing a live biotherapeutic for the treatment of inflammatory skin diseases, announced that they have entered into a definitive agreement under which Tocagen will merge with Forte in an all-stock transaction.
Galderma has announced positive results from OSCAR, a phase IV trial, a multicenter, randomized, investigator-blinded, vehicle-controlled, intra-individual comparison study (right/left...
Galderma Laboratories announced that the FDA approved antibiotic-free Epiduo Forte (adapalene and benzoyl peroxide) Gel, 0.3%/2.5%, for the once-daily, topical...
The relief of smooth muscle spasm in conditions such as irritable bowel syndrome, painful diverticular disease of the colon and primary dysmenorrhoea.
For the topical treatment of hyperhidrosis specifically involving axillae, hands or feet.